

SYNTHETIC PEPTIDE CORRESPONDING TO 30 AMINO ACIDS OF
THE C-TERMINAL OF NEURON-SPECIFIC ENOLASE PROMOTES
SURVIVAL OF NEOCORTICAL NEURONS IN CULTURE

Tatsuya Hattori¹, Keiko Ohsawa¹, Yoshikuni Mizuno², Kanefusa Kato³
and Shinichi Kohsaka^{1*}

¹Department of Neurochemistry, National Institute of Neuroscience,
Kodaira, Tokyo 187, Japan

²Department of Neurology, Juntendo University School of Medicine,
Bunkyo, Tokyo 113, Japan

³Department of Biochemistry, Institute for Developmental Research,
Aichi Prefectural Colony, Kasugai, Aichi 480-03, Japan

Received May 24, 1994

Summary: Neuron-specific enolase (NSE), one of the glycolytic enzymes, is a $\gamma\gamma$ -isozyme of enolase that is specifically expressed in neurons. Our previous studies demonstrated that NSE promotes survival of rat embryonic neocortical neurons in culture but that the $\alpha\alpha$ -isozyme (non-neuronal enolase; NNE) has no effect. In this study, we found that a synthetic peptide corresponding to the C-terminal portion of NSE (404-433) also promotes the survival of neocortical neurons. By contrast, a synthetic peptide of the C-terminal portion of NNE (404-433) has no effect on neuronal survival. These findings would be important for further analysis of the neurotrophic mechanism of NSE. © 1994 Academic Press, Inc.

Neuronal development including differentiation, maturation and survival is considered to be regulated by various neurotrophic factors in the central nervous system (CNS). We previously investigated novel neurotrophic factors in bovine brain extract by using primary cultures of embryonic rat neocortical neurons and found that one of the neurotrophic molecules is identical to neuron specific enolase (NSE), which is a $\gamma\gamma$ -isozyme of enolase (1).

Within the CNS, NSE is present only in neurons and the $\alpha\alpha$ -isozyme of enolase (non-neuronal enolase; NNE) is present in a wide variety of cells

*To whom correspondence should be addressed.

Results

As shown in Fig. 2, the synthetic peptide corresponding to 30 amino acids of the C terminal of NSE (s- γ ; residues 404-433) was found to have promoted the survival of primary cultured neocortical neurons on the fifth day of culture. This neurotrophic effect was detected at a relatively low dose and was maximum at about 20 nM. The half-maximal concentration of s- γ is about 2 nM. As reported previously, purified NSE also promoted the survival of primary cultured neurons at a lower concentration than that of s- γ , and its half-maximal concentration is about 0.3 nM. By contrast, the synthetic peptide corresponding to 30 amino acids of the C-terminal of NNE (s- α ; residues 404-433) and purified NNE did not promote the survival of primary cultured neurons.

Typical photographs of immunostained cells with MAP-2 monoclonal antibody are shown in Fig. 3. The number of MAP-2-positive cells in the culture containing purified rat NSE (2 nM) and s- γ (20 nM) was significantly higher than that in the control culture (Fig. 3A). The neuronal processes were well developed in these cultures. However,




Fig. 2. Effects of rat NSE, NNE and their synthetic peptides of the C-terminal portion. Twenty-four hours after seeding, s- γ , s- α , NSE or NNE was added to the medium and culture was continued for a further 4 days. Values indicate means \pm SD (n=4).




Fig. 3. Typical photomicrographs of cultured neocortical neurons immunocytochemically stained with anti-MAP-2 monoclonal antibody taken on the 5th day of culture. A, control; B, cultured with purified NSE (2 nM); C, with purified NNE (2 nM); D, with s- γ (20 nM); and E, with s- α (20 nM).

purified rat NNE (2 nM) and s- α (20 nM) did not alter the number of MAP-2-positive cells. Because almost all the cells were MAP-2 positive and hardly any GFAP-positive cells were detected (data not shown) in our culture system, it seems that NSE and s- γ act directly on neurons.

Discussion

We reported previously that NSE promotes the survival of rat embryonic neocortical neurons in culture (1). The glycolytic enzyme,

enolase, is present in the CNS as two isozymes, NSE ($\gamma\gamma$) and NNE ($\alpha\alpha$). NNE is found in most neural cells and NSE appears in only differentiated and mature neurons (5, 6, 7). Although the amino acid sequences of these isozymes are highly homologous, only NSE shows neurotrophic activity (1). To clarify the neurotrophic mechanism of NSE, we directed our attention to the 30 residues of the C-terminal portion of NSE and NNE, since in this portion there is a significant difference in amino acid sequence between the two isozymes (8). Interestingly, we found that s- γ (NSE 404-433) but not s- α (NNE 404-433) promotes neuronal survival. This fact led to the idea that this C-terminal region of NSE is a biologically active domain for neurotrophic activity. However, the EC_{50} of s- γ is higher than that of native NSE. One plausible explanation is that higher dimensional structure of NSE may be important for expressing neurotrophic activity.

Recently the physiological significance of the C-terminal portion of NSE has been investigated. Human autoantibodies against the C-terminal region of amyloid β /A4-protein (residues 29-40) have been found in Alzheimer's disease patients (9). It was reported that an antibody against a synthetic C-terminal peptide of amyloid β /A4-protein (residues 28-40) cross-reacted with NSE but not with NNE. The cross-reacting epitope was considered to be residues 402-423 of NSE (10). This domain is mainly hydrophilic in character and is located on the surface of the three-dimensional structure of NSE (2). These residues seem to represent one of the antigenic determinant regions among enolase isozymes (8).

Most discussions of the role of NSE in neurons include its function as a metabolic enzyme (11). However, our previous findings (1) together with the present results also raise the possibility that NSE plays certain roles in the CNS for regulating neuronal development and maintenance. The present findings could be an important clue to clarify the neurotrophic mechanism of NSE in the CNS.

Acknowledgments

The present studies were supported by grants from the Ministry of Health and Welfare and the Japan Health Science Foundation and by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science and Culture.

References

1. Takei, N., Kondo, J., Nagaike, K., Ohsawa, K., Kato, K., and Kohsaka, S. (1991) *J. Neurochem.* **57**, 1178-1184.
2. Forss-Petter, S., Danielson, P., and Sutcliffe, J. G. (1986) *J. Neurosci. Res.* **16**, 141-156.
3. Suzuki, F., Ueda, Y., and Kato, K. (1980) *J. Biochem.* **87**, 1587-1594.
4. Takei, N., Ohsawa, K., Imai, Y., Nakao, H., Iwasaki, A., and Kohsaka, S. (1994) *Neurosci. Lett.* in press.
5. Marangos, P. J., Schmechel, D. E., Parma, A. M., and Goodwin, F. K. (1980) *Brain Res.* **190**, 185-193.
6. Kato, K., Suzuki, F., and Semba, F. (1981) *J. Neurochem.* **37**, 998-1005.
7. Sakimura, K., Kushiya, E., Obinata, M., Odani, S., and Takahashi, Y. (1985) *Proc. Natl. Acad. Sci. USA.* **82**, 7453-7457.
8. McAleese, S. M., Dunbar, B., Fothergill, J. E., Hinks, L. J., and Day, N. M. (1988) *Eur. J. Biochem.* **178**, 413-417.
9. Gaskin, F., Finley, J., Fang, Q., Xu, S., and Fu, S. M. (1993) *J. Exptl. Med.* **177**, 1181-1186.
10. Harrington, C. R., Qinn, G. B., Hurt, J., Day, I. N. M., and Wishik, C. M. (1993) *Biochimica et Biophysica Acta.* **1158**, 120-128.
11. Marangos, P. J., and Schmechel, D. E. (1987) *Annual Review of Neurosci.* **10**, 269-295.